 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Cynosure (CYNO) develops, manufactures, and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets.
Its aesthetic treatment systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag, and diode lasers, as well as intense pulsed light.
The companys aesthetic treatment systems comprise the Elite product line for hair removal, treatment of facial, and leg veins and pigmentations; the Smartlipo product line for LaserBodySculpting for the removal of unwanted fat; the Cellulaze, SmoothShapes XV, and TriActive product line for the temporary and long-term reduction in the appearance of cellulite; the Affirm/SmartSkin product line for anti-aging applications, such as treatments for wrinkles, skin texture, skin discoloration, and skin tightening; the Cynergy product line for the treatment of vascular lesions; and the Accolade, MedLite C6, and RevLite product line for the removal of benign pigmented lesions, as well as multi-colored tattoos. It also distributes the PinPointe FootLaser, a light-based device for the treatment of onychomycosis.
The company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Korea, China, Japan, and Mexico, as well as through international distributors in 97 other countries.
Shares have formed a bullish "flag" after the firm reported earnings that beat on the top and bottom lines. Higher prices are expected from this formation. Cynosure reported revenue of $37.1 million, above the $34.6 million expected. EPS came in at $0.25, well above the estimates of $0.12 per share. A year ago the firm had reported EPS of -$0.06.
52-Week Trading Range: $10.79 - $28.00
Last Trade: $27.27
Stop Loss: $25.90
Target Price: $30.00
CYNO dropped below our stop loss following its shares offering.
